跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Allergopharma GmbH & Co. KG

首页临床试验发起方与机构Allergopharma GmbH & Co. KG

Allergopharma GmbH & Co. KG

ACTIVE

Hermann-Körner-Str. 52-54, Reinbek, Schleswig-Holstein, 德国www.allergopharma.deSubsidiary成立于: 1969-01-01

别名:

paketanschrift

隶属于 dermapharm holding se

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

46

23 进行中

药物批准

3

批准总数

监管机构

1

监管机构数

成立时间

1969

概览

试验阶段分布

阶段

试验数

占比

1 期

20

43.5%

3 期

14

30.4%

2 期

6

13.0%

4 期

2

4.3%

试验状态分布

进行中（未招募）

22

47.8%

已完成

21

45.6%

尚未招募

1

2.2%

招募中

1

2.2%

终止

1

2.2%

相关临床试验

该机构主办的试验（46）

Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites

Jul 2025105 名受试者

Prospective, multi-centre, non-interventional study on the use, tolerability and safety of the One Strength dose escalation scheme with NOVo Helisen® hoUSe dust mites in everyday practice

Aug 20231000 名受试者

Study to investigate the safety of an accelarated (fast) dose escalation schedule using one strength birch pollen allergens as compared to the approved long (slow) two-dose escalation in adult and pediatric patients with allergic cold (with and w/o asthma).

进行中（未招募）

Dec 2021210 名受试者

Study to investigate the safety of an accelarated (fast) dose escalation schedule using one strength birch pollen allergens as compared to the approved long (slow) two-dose escalation in adult and pediatric patients with allergic cold (with and w/o asthma).

进行中（未招募）

Nov 2021210 名受试者

Study to investigate the safety of a short (fast) dose escalation in immune therapy with house dust mite allergens as compared to the approved long (slow) dose escalation in adult and adolescent patients with allergic cold (with and w/o asthma).

进行中（未招募）

Apr 2021140 名受试者

Study to investigate the safety of a short (fast) dose escalation in immune therapy with house dust mite allergens as compared to the approved long (slow) dose escalation in adult and adolescent patients with allergic cold (with and w/o asthma).

进行中（未招募）

Apr 2021140 名受试者

A clinical study conducted in several test centers to investigate the safetyof an accelerated high dose escalation schedule for an immune therapy in pediatric patients with hayfever with or without asthma.

进行中（未招募）

Aug 2018140 名受试者

A clinical study conducted in several test centers to investigate the safety of an accelerated high dose escalation schedule for an immune therapy in pediatric patients with hayfever with or without asthma.

进行中（未招募）

Jun 2018140 名受试者

第 1 页，共 6 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

3

药物批准

近期批准

Novo-Helisen-Depot(NHD)

Novo-Helisen-Depot(NHD)

Novo-Helisen-Depot(NHD)

资讯

暂无资讯文章

本页目录

概览
相关临床试验46
药物批准3
资讯

返回机构列表